Tafamidis – 5 mg

Brand:
Cayman
CAS:
594839-88-0
Storage:
-20
UN-No:
Non-Hazardous - /

Tafamidis is a kinetic stabilizer of transthyretin (TTR) that prevents amyloidogenesis by wild-type and mutant TTRs.{38438} It binds to TTR with negative cooperativity (Kd1 = 3 nM; Kd2 = 278 nM) to stabilize the TTR dimer-dimer interface and inhibit tetrameric dissociation. Tafamidis stabilizes wild-type and clinically significant V30M and V122I mutant TTR amyloidogenic homotetramers (EC50s = 2.7-3.2 μM) under fibril-promoting, denaturing, and physiological conditions in vitro. It stabilizes TTR heterotetramers containing wild-type and mutant subunits ex vivo in human plasma derived from patients carrying V30M or V1221 mutations when used at a concentration of 7.2 μM. Formulations containing tafamidis have been used for the treatment of familial amyloid polyneuropathy.{38439}  

 

SKU: - Category:

Description

A TTR kinetic stabilizer; binds to TTR with negative cooperativity (Kd1 = 3 nM; Kd2 = 278 nM) to stabilize the TTR dimer-dimer interface and inhibit tetrameric dissociation; stabilizes wild-type and clinically significant V30M and V122I mutant TTR amyloidogenic homotetramers (EC50s = 2.7-3.2 μM) under fibril-promoting, denaturing, and physiological conditions in vitro; stabilizes TTR heterotetramers containing wild-type and mutant subunits ex vivo in human plasma derived from patients carrying V30M or V1221 mutations when used at a concentration of 7.2 μM,


Formal name: 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylic acid

Synonyms:  PF-06291826

Molecular weight: 308.1

CAS: 594839-88-0

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals||Research Area|Neuroscience|Neurodegenerative Disorders